Kfar Saba, Israel (ots/PRNewswire) - CartiHeal Ltd., developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today announced its first commercial implantation of Agili-C in the US by Dr. Ken Zaslav, a specialist in Orthopedic Surgery and Sports Medicine at Northwell Health in New York City, NY. The ...
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
Kfar Saba, Israel (ots/PRNewswire) - Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint CartiHeal Ltd, developer of implants for the treatment of cartilage and ...
Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...
Kfar Saba, Israel (ots/PRNewswire) - According to a Two-Year Randomized and Controlled Multinational IDE Study CartiHeal Ltd, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device Designation by the FDA last ...
Mechelen, Belgium and Paris (ots/PRNewswire) - Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three ...
Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ...
Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C(TM) implant, as part of Investigational Device Exemption (IDE) clinical study by Dr. ...
Madrid (ots/PRNewswire) - QUANTIC NANOTECH (https://qnanotech.com/), a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system "QNANO GLOVE (https://qnanotech.com/)" during the last CES 2019 Edition in Las Vegas, announced today the opening of free ...
The procedure was performed by Joseph M. Berman, MD, an orthopedic surgeon at Arlington Orthopedics Associates (AOA), Arlington, TX Kfar Saba, Israel (ots/PRNewswire) - - CartiHeal (http://www.cartiheal.com/), developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first ...
Two patients were enrolled and operated on by sports medicine surgeon Andreas Gomoll, MD Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the successful enrollment and ...
Not intended for UK or U.S. based media Darmstadt, Germany (ots/PRNewswire) - - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that data from ...
Four patients enrolled and operated on by sports medicine surgeon Dr. Seth L. Sherman, MD Kfar Saba, Israel (ots/PRNewswire) - Seth L. Sherman, MD, a sports medicine orthopaedic surgeon at Missouri Orthopaedic Institute, recently became one of the first American surgeons to enroll patients in a clinical research ...